CVTX - CV Therapeutics, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (355)	11/11/2008 8:54:12 PM
From: Biomaven	Read Replies (2) of 411

>>new-onset patients who choose ranexa Well it's still not first line, so undoubtedly they will be put on beta blockers, etc. first. An angina attack is no small thing for most folks, so I'm pretty sure most patients will happily add a couple of pills a day to avoid one extra attack a week. Personally I think European sales will be an important key. They use medication much more than surgical intervention there, so potentially the market there is bigger than the US market (although don't know anything about pricing). This is the sort of drug where sales build slowly but surely over several years. These patients don't get better, and if it works they will stay on it. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next